RRML - Lupus anticoagulant in children – a confounding factor in diagnosis and targeted therapy

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- February 2024 -
Anti-thyroid peroxidase (TPO) ... 18
Romanian Review of Laboratory ... 17
Recomandarea comună EFLM-COLA... 13
Approaching Risk Management in... 12
Identification of shared hub g... 12
Challenges in prophylactic the... 12
Monocyte to high-density lipop... 9
Atellica CH 930 chemistry anal... 8
Setting up an own laboratory p... 7
Understanding the key differen... 7

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 29(3)/2021 DOI:10.2478/rrlm-2021-0021

Research article

Lupus anticoagulant in children – a confounding factor in diagnosis and targeted therapy

Cristian Jinca, Margit Serban, Emilia Ursu, Nicoleta Anamaria Pascalau, Oana Belei, Delia Savescu, Mihaela Lelik, Andrei Ioan Munteanu, Andreas Tiede, Smaranda Arghirescu

Correspondence should be addressed to: Cristian Jinca


Introduction: Lupus anticoagulant (LAC) belongs to a heterogeneous group of antibodies directed against negatively charged phospholipid-binding proteins, inhibiting phospholipid-dependent reactions. We assessed the frequency, etiological background, clinical and biological expression as well as the appropriate management and outcome of LAC in a pediatric population. Patients and methods: We included 19 pediatric patients diagnosed with a positive LAC test during a period of 1 year. LAC detection was carried out according to the ISTH/SCC guidelines 2012. Coagulometric assays were performed in order to check for coagulation factor activities. The presence of specific inhibitors has been tested by the Bethesda assay. Results: LAC was positive in 0.4% of the patients monitored for increased activated partial thromboplastin time (aPTT) during the study period of 1 year. In contrast to the asymptomatic clinical image presented by the majority of our patients, the biological picture was dominated by an elevated aPTT (79 %), the aPTT ratio correlating significantly with the strength of LAC. In 58 % of the patients LAC became negative within 12 weeks, in another 4 (21%) patients within 20 weeks, whereas in 4 (21%) patients LAC remained positive throughout the follow-up. Conclusion: Albeit usually innocent in asymptomatic patients, LAC needs to be seriously taken into consideration from the diagnostic point of view in order to avoid dangerous therapeutic attitudes.

Keywords: antiphospholipid syndrome, acquired hemophilia, activated partial thromboplastin time, lupus anticoagulant

Received: 19.3.2021
Accepted: 21.6.2021
Published: 10.7.2021

  PDF Download full text PDF
(640 KB)
How to cite
Jinca C, Serban M, Ursu E, Pascalau NA, Belei O, Savescu D, et al. Lupus anticoagulant in children – a confounding factor in diagnosis and targeted therapy. Rev Romana Med Lab. 2021;29(3):287-98. DOI:10.2478/rrlm-2021-0021